Amarin Corp Plcuk (AMRN) Gains from Sales and Divestitures (2013 - 2025)
Amarin Corp Plcuk (AMRN) reported Gains from Sales and Divestitures of $8.5 million for Q4 2025, up 121.78% year-over-year from $3.9 million in Q4 2024, and up 121.78% quarter-over-quarter from $3.9 million in Q4 2024.
Amarin Corp Plcuk (AMRN) Gains from Sales and Divestitures (2013 - 2025) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 12 years of Gains from Sales and Divestitures data on file, last reported at $8.5 million in Q4 2025.
- Gains from Sales and Divestitures for Q4 2025 came in at $8.5 million, up 121.78% year-over-year; the trailing twelve-month figure through Dec 2025 was $8.5 million (up 121.78% YoY), and the FY2025 annual result was $8.5 million, up 121.78% from the prior year.
- Gains from Sales and Divestitures grew to $8.5 million in Q4 2025 per AMRN's latest filing, from $3.9 million in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $8.5 million in Q4 2025 and troughed at $1.9 million in Q4 2022.
- A 5-year average of $4.5 million and a median of $4.1 million in 2021 frame the typical range for Gains from Sales and Divestitures.
- The sharpest annual moves came in 2022 and 2025: Gains from Sales and Divestitures sank 52.18% in 2022, then jumped 121.78% in 2025.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $4.1 million in 2021, then slumped by 52.18% to $1.9 million in 2022, then soared by 119.02% to $4.2 million in 2023, then slipped by 9.34% to $3.9 million in 2024, then soared by 121.78% to $8.5 million in 2025.
- Business Quant data shows AMRN's Gains from Sales and Divestitures at $8.5 million in Q4 2025, $3.9 million in Q4 2024, and $4.2 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.54 Mn |
| Dec 31, 2025 | 8.54 Mn |
| Dec 31, 2024 | 3.85 Mn |
| Dec 31, 2024 | 3.85 Mn |
| Dec 31, 2023 | 4.25 Mn |
| Dec 31, 2023 | 4.25 Mn |
| Dec 31, 2022 | 1.94 Mn |
| Dec 31, 2022 | 1.94 Mn |
| Dec 31, 2021 | 4.06 Mn |
| Dec 31, 2021 | 4.06 Mn |
| Dec 31, 2020 | 2.51 Mn |
| Dec 31, 2020 | 2.51 Mn |
| Dec 31, 2019 | 3.97 Mn |
| Dec 31, 2019 | 3.97 Mn |
| Dec 31, 2018 | 4.61 Mn |
| Dec 31, 2018 | 4.61 Mn |
| Dec 31, 2017 | 2.18 Mn |
| Dec 31, 2017 | 2.18 Mn |
| Dec 31, 2016 | 1.85 Mn |
| Dec 31, 2016 | 1.85 Mn |